Pia Renaudin joins as new CEO at Senzime

Press release: Uppsala, February 7th, 2019.
Pia Renaudin assumes her position as the new CEO of Senzime AB (publ).

Senzime announced on the 19th of November 2018 the appointment of Pia Renaudin as new CEO. Pia has of today assumed her position and succeeds Catrin Molund in her capacity as acting CEO.

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                                                                                 

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com        

TO THE EDITORS

About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399 is Certified Adviser for Senzime. www.senzime.com

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on February 7th, 2019 08:45 

Tags: